Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice
Objectives Dipeptidyl peptidase-4 inhibition and gastric inhibitory polypeptide (GIP) receptor antagonism have therapeutic effects in type 2 diabetes mellitus. We assessed the effects of sitagliptin and Pro 3 (GIP) in a mouse model of diabetes. Methods Diabetes was induced in C57BL/6J mice by a high...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-01-01
|
Series: | Journal of International Medical Research |
Online Access: | https://doi.org/10.1177/0300060520985664 |